Erlotinib is an inhibitor of EGFR and has been approved to treat non-small cell lung and pancreatic cancers and was shown to exert multifarious antineoplastic effects in glioblastoma in preclinical studies (70, 71). The gene discussed is EGFR; the disease is pancreatic neoplasm.